INOVA DIAGNOSTICS, INC.

INOVA DIAGNOSTICS, INC. specializes in the manufacturing of biological products, excluding diagnostic agents, with a focus on the development and production of biologically derived materials for research or therapeutic applications. Their technical expertise lies in controlled biological manufacturing processes, including cell culture, purification, and aseptic formulation under GMP-aligned protocols. While specific product types are not disclosed in available award data, their work implies deep competency in upstream and downstream bioprocessing, quality control for biologicals, and regulatory compliance for non-diagnostic biologics. Their differentiation stems from precision in scalable production of complex biological entities, likely serving specialized research or clinical needs within regulated environments. The contractor has delivered services exclusively to the Department of Health and Human Services, indicating a focused relationship with federal health research and development initiatives. This engagement suggests alignment with HHS components such as NIH or CDC, where biological product manufacturing supports vaccine development, biologics research, or therapeutic pipeline advancement. The nature of the award implies a contract vehicle tied to scientific procurement rather than commercial procurement, pointing to a niche role in supporting public health innovation. Their primary industry focus is on NAICS 325414, which encompasses the manufacturing of biological products such as blood derivatives, recombinant proteins, or other non-diagnostic biologics. This positions INOVA DIAGNOSTICS, INC. within the broader biopharmaceutical supply chain, serving government-funded biomedical research and development rather than commercial diagnostics or consumer health markets. The company operates at the intersection of biomanufacturing and federal science policy, supporting mission-critical biological supply needs. The entity structure, certifications, and geographic presence are not disclosed in available records. There is no indication of small business, HUBZone, or other government certifications. The company’s market positioning appears specialized and confined to direct federal biomanufacturing contracts, with no evidence of broad commercial or multi-agency presence.